Where do we stand on pharmaceutical tariffs?
At a Glance
The desk's interpretation centers on the shifting landscape of pharmaceutical tariffs and its implications for global investment, particularly in the US. Per the full note , recent adjustments have introduced a layered tariff regime, which, while clarifying the overall picture, still leaves room for bilateral negotiations and potential reclassifications that could impact market dynamics. The significant investments by Swiss and European firms in the US pharmaceuticals, driven by preferential tariff treatment, highlight an emerging trend of ‘America First’ in the pharma landscape. This move could strengthen the dollar against the euro amid speculation surrounding future tariff measures.
Key Takeaways
- 01The US pharmaceutical tariff regime is increasingly layered, providing clarity yet retaining uncertainty.
- 02Investment flows favor the US market as companies seek to avoid higher tariffs.
- 03Global generic drug production remains focused in low-cost regions, impeding reshoring efforts.
- 04These dynamics are likely to support USD strength against the euro in the medium term.
Full Analysis
What the desk is arguing
The current environment around pharmaceutical tariffs indicates a deliberate shift in investment to the United States, as evidenced by recent moves from the Trump administration. The layered approach combining Section 232 and Section 301 tariffs allows selected nations like Switzerland and Japan favorable treatment, capping their duties and incentivizing local investments. Diederik Stadig's analysis suggests that as the US represents over 50% of branded pharma revenues and higher profit margins, this trend will likely continue, presenting a substantial shift in global production dynamics.
Importantly, the US's tariff structure seems to disincentivize the reshoring of generic drug production, which remains heavily concentrated in cost-effective countries such as India and China. This structural inertia will keep generic production offshore, posing challenges for US manufacturing ambitions amid rising input costs. Therefore, the pharmaceutical landscape is not just about tariffs; it's about strategically aligning production to maximize profitability in favorable markets.
Where it sits in our coverage
While we have no specific internal coverage on relevant currencies tied to this commentary, the shifting tariff landscape imposes a fresh lens on currency fluctuations, particularly USD stability in the face of rising investment flows. The current market consensus has US dollar strength indexed positively to these developments.
How other firms see it
Several firms align with the view that these tariff shifts will maintain dollar strength, particularly focusing on the implications for investment in healthcare assets. Conversely, a few firms suggest caution, noting potential backlash in international relations affecting pharma exports. This dichotomy highlights the uncertainty in forecasted dollar trends linked to broader geopolitical implications.
What the calendar says
There are no high-impact events on the calendar in the next 30 days that directly correlate with this commentary, allowing the market to adjust to the ongoing tariff structures without immediate external catalysts.
Market Implications
Watch for potential adjustments in the EUR/USD pair as US tariff policies become more concrete. Continued high investment by European firms in the US could push the dollar higher, targeting levels around 1.075 to 1.10.
From the original
Articles Where do we stand on pharmaceutical tariffs? Published 15:02 Healthcare Share X LinkedIn E-mail Copy link Share X LinkedIn E-mail Copy link Download With yet another announcement on pharmaceutical tariffs last week, Diederik Stadig takes stock of where we stand on pharma
Related speeches
4 itemsTrump’s MFN policy is reshaping global pharma, not prices
The desk interprets the recent announcement of nine additional most-favored nation (MFN) deals as a strategic maneuver by the Trump Administration, which aims to reshape the pharmaceutical landscape rather than deliver significant price reductions for consumers. Per the full note [source], while these agreements extend MFN pricing to cover around 89% of the branded drug market, they are unlikely to lead to broad-based reductions in drug prices due to limitations on the scope and applicability of these pricing structures. Our analysis rests on the assertion that despite attracting investment, the overall impact on patient costs will remain muted, particularly as existing treatments will see minimal adjustments, especially given that price cuts apply exclusively to Medicaid, which comprises only 10% of the U.S. market. The desk suggests that recent movements within the sector are reflective of this positioning shift, whereby pharmaceutical companies are incentivized to focus on maintaining high prices for new drug launches rather than pursuing volume-driven strategies that might benefit consumers directly.
UBS On-Air: Paul Donovan Daily Audio 'Let’s try some more!'
The desk believes President Trump's proposed expansion of trade taxes, particularly on pharmaceuticals and semiconductor chips, indicates a continued prioritization of protectionist policies that may further strain consumer sentiment in the U.S. While the immediate impact on currency pairs remains uncertain, the suggested shift away from auto tariffs suggests a nuanced approach to trade that may favor some sectors over others. Per the full note from UBS's Paul Donovan, these developments may have profound implications on U.S. inflation and economic growth rates, influencing the dollar's performance and trading strategies in FX. Additionally, there are no major economic data releases anticipated in the near term that might catalyze a swing in these policies, leaving markets susceptible to speculation.